関連する実験動画
Updated: May 2, 2026

14:09
Genetic Studies of Human DNA Repair Proteins Using Yeast as a Model System
Published on: March 18, 2010
18.1K
国立老化研究所からの視点
1National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Journal of the American Geriatrics Society
|August 28, 2025
まとめ
全国認知症労働力調査 (NDWS) は認知症ケア労働力を評価する最初の大規模な調査です. アルツハイマー病やそれに関連する認知症の 増加する人口に対する 医療の質と成果を改善するために 重要なデータを提供しています
科学分野:
- ゲロントロジー
- 医療サービス研究
- 公衆衛生
背景:
- アルツハイマー病と関連する認知症 (AD/ADRD) の流行が増加しているため,強固で安定した認知症ケアスタッフが必要になります.
- 高品質の認知症のケアを保証するには,この労働力の人口統計,課題,経験を理解することが重要です.
- 現存する知識の不足は,認知症のケアスタッフに関する包括的な国内データが必要であることを強調しています.
研究 の 目的:
- 認知症の医療従事者に対する最初の大規模な全国調査を実施する.
- 認知症ケアにおける専門職と直接ケアワーカーが直面する人口統計,経験,課題に関するデータを収集する.
- 認知症の治療の質と結果に影響を与える労働力要因を分析するためのデータインフラを構築する.
主な方法:
- 全国認知症労働力調査 (NDWS) は,大規模な全国調査の設計を採用しました.
- データ収集には医師,高度な診療の提供者,看護師,直接ケアワーカー,その他の医療従事者が含まれていました.
- この研究には4つの主要な介護施設が含まれる. 地域医療,介護施設,介護生活,家庭介護です.
- Medicareの請求書と他の健康データベースとの革新的なデータリンクが利用されました.
主要な成果:
- 最初のNDWSデータセットは2025年7月にリリースされ,無料で利用できます.
- リンクされたNDWS-Medicareデータセットは,安全なウェブポータルを通じて分析できます.
- この研究は 認知症の医療従事者に関する新しい疑問に 答えられる基盤を提供します
結論:
- NDWSの調査結果は,米国における認知症ケア労働力の未来を形作る戦略に役立つでしょう.
- この研究は 認知症の患者数が増える中で 質の高いケアを提供することを目的としています
- 縦断的な結果と年次更新は 研究者,実務者,政策立案者に継続的な洞察を提供します.
関連する概念動画
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Pharmacodynamics in Geriatric Patients: Effects of Age
367
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
367
Aging
1.1K
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
1.1K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35

